Hold BMY: Maintain 1.0-1.5% weight for dividend carry and structural floor; binding reflections reject 30-40% trim and Underweight
Hold BMY. The 9/10/9/11 BMY reflections are dispositive and bind against the proposed trim magnitude. The floor thesis retains multi-analyst consensus integrity: all three current analysts agree beta 0.227, 2.5x FCF coverage ($12-14B FCF vs $5B payout), $6.1B debt reduction over four quarters, 200 SMA at $57.78 intact, and 71.6% gross margin constitute genuine defensive floor. New structural concerns (hurdle rate failure, CYTK overhang, earnings gap) compress the multiple but do not break the floor thesis. Reject trader's Sell/30-40% trim and Research Manager's Underweight as conflicts with binding constraints. Reject PFE rotation per all three analysts. Stop at $61.50. Trim trigger on 50 SMA break at $63.55. Add triggers tied to technical repair at $66.20 and 200 SMA hold at $57.78. Full re-evaluation after Q3 2026 earnings and CYTK ruling.
| Position | Action |
|---|---|
| Current residual position post 9/8 and 9/10 trims | Maintain 1.0-1.5% portfolio weight for 3.96% dividend carry |
| Close below 50 SMA at $63.55 on above-average volume | Trim/exit remainder immediately (binary technical decision point) |
| Weekly close below 200 SMA at $57.78 | Full exit (deeper fundamental deterioration) |
BMY is undergoing a pipeline transformation from a legacy Eliquis/Revlimid story to a diversified oncology + cell therapy + neuro franchise, with the recovery already evident in H1 2026 earnings that exceed full-year 2025, creating a compelling patient capital opportunity at a 9.77 forward P/E with 3.96% yield and asymmetric technical support near $63.23.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $65.14 | bearish |
| 50 SMA | $63.55 | neutral |
| 200 SMA | $57.78 | bullish |
| RSI(14) | 45.00 | neutral |
| MACD Line | 0.16 | bearish |
| MACD Signal | 0.78 | bearish |
| MACD Histogram | -0.61 | bearish |
| Bollinger Upper | $69.16 | neutral |
| Bollinger Middle | $66.20 | neutral |
| Bollinger Lower | $63.23 | neutral |
| ATR(14) | $1.47 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed test and hold of 200 SMA at $57.78 with bullish daily divergence AND no further CYTK escalation
Then: Add 25% of intended incremental size
The patent cliff is a known, priced-in event, not a sudden catastrophe, and BMY's pipeline is being actively rebuilt.
↩ rebuts: “Bear case that patent cliff represents unpriced existential risk”
· concedes: Patent cliff is real and no serious analyst should pretend otherwise; Eliquis faces loss of exclusivity; Cytokinetics likely has the upper hand per RBC analysis; The 10-year above 5% is the most legitimate bear concern; Revenue is flat at $49.2 billion TTM; RSI at 45 and MACD negative histogram near-term; BMY is dependent on BD deals to replenish pipeline
BMY is a stock trading on hope, not earnings—the patent cliff is deferred, not priced in, and the risk/reward is asymmetric to the downside.
EV: Bull case upside: +9% to +17% (to $70–$75) plus 4% yield = 13–21% total return; Bear case downside: -11% (to $57) with potential dividend pressure · concedes: H1 2026 underlying earnings growth of +10–15% YoY is meaningful; The Karuna, Mirati, RayzeBio M&A was capital-efficient relative to building internally; The low beta does provide downside protection in market sell-offs; Healthcare sector outperformed SPX by 16.7 ppt, showing sector rotation favor
→ vs conservative: Conservative's 'dividend is safe' framing misses that the 3.96% yield fails the competitive hurdle test against a 5%+ risk-free rate — the income cushion is actually a discount that compresses the willing buyer base for the equity itself
→ vs conservative: Conservative wants to credit BMY for arlo-cel like an earnings catalyst, but this is heavily pretreated fourth-line+ multiple myeloma with regulatory conversion years out — the addressable population is smaller than implied and realistic revenue contribution doesn't arrive until back-half 2028 at earliest
→ vs neutral: The neutral analyst's chart work lets the 'story of the tape' override the 'message of the tape' — the 50 SMA at $63.55 has zero structural volume behind it and waiting for breakdown confirmation is 'the kind of patience that turns a trim into a loss'
→ vs neutral: The neutral analyst wants to 'wait for confirmation of the breakdown' — but that path leads to selling lower after the technicals actually break or watching a 10-15% drawdown because you anchored to the bull narrative at $64
| neutral |
Support: 63.55 · 63.23 · 62 · 60 · 57.78 | Resistance: 66.2 · 68.64 · 69.16
The technical picture shows a pullback within a confirmed long-term uptrend. Price at $64.10 sits just above the 50 SMA support at $63.55, with the lower Bollinger band at $63.23 as the immediate breakdown level. The 200 SMA at $57.78 represents the bull-bear trend line. MACD has decelerated but remains positive (+0.16), consistent with a correction rather than a reversal. RSI at 45.00 has reset from overbought (peak 72.79 on Aug 4) but is not yet oversold. A hold above $63.23 followed by MACD histogram narrowing and RSI curling up would be a constructive re-entry signal toward $66.20-$68.64.
Market Cap
$130.94 B
Share Price (implied)
~$64
52-Week Range
$42.52 – $68.64
50-Day Moving Avg
$63.43
200-Day Moving Avg
$58.49
P/E (TTM)
14.12
Forward P/E
9.77
Forward EPS
$6.56
TTM EPS
$4.54
PEG Ratio
17.72
Price/Book
5.87
Dividend Yield
3.96%
Beta
0.227
Revenue (TTM)
$49.19 B
Gross Profit
$35.25 B
EBITDA
$18.93 B
Net Income (TTM)
$9.28 B
Operating Margin
34.42%
Net Profit Margin
18.87%
ROE
46.60%
ROA
10.72%
Q2 2026 Revenue
$12.97 B
Q2 2026 Net Income
$3.32 B
Q2 2026 Diluted EPS
$1.62
Q1 2026 Revenue
$11.49 B
Q1 2026 Net Income
$2.68 B
Q1 2026 Diluted EPS
$1.31
Q4 2025 Revenue
$12.50 B
Q4 2025 Net Income
$1.09 B
Q4 2025 Diluted EPS
$0.53
Q3 2025 Revenue
$12.22 B
Q3 2025 Net Income
$2.20 B
Q3 2025 Diluted EPS
$1.08
2025 Revenue
$48.20 B
2025 Net Income
$7.05 B
2025 Diluted EPS
$3.46
2024 Revenue
$48.30 B
2024 Net Income
($8.95) B
2024 Diluted EPS
($4.41)
2023 Revenue
$45.01 B
2023 Net Income
$8.03 B
2023 Diluted EPS
$3.86
2022 Revenue
$46.16 B
2022 Net Income
$6.33 B
2022 Diluted EPS
$2.95
Total Assets
$87.63 B
Stockholders' Equity
$22.32 B
Total Debt
$45.05 B
Net Debt
$34.40 B
Tangible Book Value
($17.05) B
Working Capital
$9.92 B
Current Ratio
1.53
Debt/Equity
~202%
Goodwill
$21.7 B
Other Intangibles
$17.6 B
2025 Operating Cash Flow
$14.16 B
2024 Operating Cash Flow
$15.19 B
2023 Operating Cash Flow
$13.86 B
2022 Operating Cash Flow
$13.07 B
2025 Free Cash Flow
$12.85 B
2024 Free Cash Flow
$13.94 B
2023 Free Cash Flow
$12.65 B
2022 Free Cash Flow
$11.95 B
2025 CapEx
$1.31 B
2024 CapEx
$1.25 B
2023 CapEx
$1.21 B
2022 CapEx
$1.12 B
2025 Dividends Paid
$5.05 B
2024 Dividends Paid
$4.86 B
2023 Dividends Paid
$4.74 B
2022 Dividends Paid
$4.63 B
2025 Net Debt Repayment
$5.18 B
2024 Net Debt Issuance
$10.10 B
2023 Net Debt Repayment
$0.46 B
2022 Net Debt Repayment
$5.31 B
2023 Share Repurchases
$5.16 B
2022 Share Repurchases
$8.00 B
Annualized Dividend
~$2.50
Annual Dividend Payout
~$5.0 B
Payout Ratio
~50%
Q2 2026 OCF
$3.39 B
Q2 2026 FCF
$3.09 B
Q1 2026 OCF
$1.10 B
Q1 2026 FCF
$0.76 B
Q4 2025 OCF
$1.97 B
Q4 2025 FCF
$1.60 B
Q3 2025 OCF
$6.31 B
Q3 2025 FCF
$5.99 B
TTM Free Cash Flow
$8.11 B
Strengths
Concerns
Bristol-Myers Squibb Company (BMY) is a large-cap global biopharmaceutical company with a market cap of $130.94B, trading at ~$64 near 52-week highs, offering a defensive profile (Beta 0.227) and attractive 3.96% dividend yield. The company reported TTM revenue of $49.19B (flat) with net income of $9.28B, recovering from a $8.95B loss in 2024 driven by $13.9B in acquisition-related impairments. The forward P/E of 9.77 with projected EPS growth from $4.54 to $6.56 reflects market expectations for recovery from new product launches (Cobenfy, Krazati), while the company aggressively deleverages (debt reduced ~$5.8B YoY to $45.05B) and generates robust $13–14B annual operating cash flow. Key risks include revenue stagnation, Eliquis patent cliff exposure, and elevated debt load with negative tangible book value of ($17.05)B.
Macro: The dominant macro backdrop features a 10-year Treasury yield crossing 5% intraday (multi-year high), with 94% implied odds of zero Fed rate cuts in 2026 (up 1.4 ppt WoW). U.S. recession probability by year-end 2026 is priced at just 10% (up 3 ppt WoW), suggesting a soft-landing baseline. Higher long rates create a headwind for dividend-paying equities as BMY's ~4% yield must now clear a 5%+ risk-free hurdle. Macro hard data (CPI, PCE, unemployment) unavailable this session due to FRED feed offline.